English
简体中文
Total: £ 56.28
Published Date: 2026-04-02 | Pages: 110 | Tables: 113 | Pharma & Healthcare
The global DPT Vaccines market was valued at US$ 5964 million in 2025 and is anticipated to reach US$ 7562 million by 2032, at a CAGR of 3.5% from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on DPT Vaccines competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
In 2024, global DPT Vaccines production reached approximately 350 million doses, with an average global market price of around US$ 16 per square meter. The DPT vaccine or DTP vaccine is a class of combination vaccine against three infectious diseases in humans: diphtheria, pertussis (whooping cough), and tetanus. In this report, we cover all the DTP-containing vaccines. Gross margin for the DPT Vaccines in general shows that manufacturers often achieve roughly 50–70% gross margins, depending on the producer, country, and contract.
The global DPT Vaccines market continues to grow steadily, driven by rising awareness of whooping cough, expanding childhood immunization programs, and increasing recommendations for adolescent and adult Tdap boosters. Demand is especially strong in developing regions where pertussis remains endemic, while mature markets are supported by routine pregnancy immunization and periodic booster campaigns. Major manufacturers focus on improving vaccine safety, supply stability, and combination formulations such as DTaP, which simplify national immunization schedules. Although pricing and procurement are heavily influenced by government tenders and international organizations, overall market growth is supported by public-health initiatives, technological advances in acellular vaccine production, and efforts to increase global vaccination coverage. The DPT Vaccines industrial chain is a complex, highly regulated, and technology-intensive ecosystem that spans from upstream antigen research to downstream global immunization delivery. It is characterized by significant barriers to entry, stringent quality control, and a delicate balance between public health objectives and commercial viability. The chain begins with basic and applied research into Bordetella pertussis antigens. This includes the identification, genetic sequencing, and optimization of key immunogenic components such as Pertussis Toxin (PT), Filamentous Hemagglutinin (FHA), Pertactin (PRN), and Fimbrial proteins (FIM). For acellular vaccines (aP), the upstream segment involves mastering large-scale fermentation, toxin purification, and detoxification (converting PT to Toxoid) processes. This stage also encompasses the production of specialized adjuvants (e.g., aluminum salts) and critical raw materials for cell culture media and buffers. Innovation here focuses on improving antigen yield, purity, stability, and developing novel adjuvant systems to enhance and prolong immunity. The demand for DPT Vacciness is driven by the persistent prevalence of whooping cough, growing awareness of immunization benefits, and expanding vaccination programs for infants, adolescents, and adults. Rising adoption of Tdap boosters during pregnancy and among healthcare workers further fuels market growth. Opportunities exist in developing countries where vaccination coverage is still limited, as well as in urban areas of developed nations with increasing focus on adult immunization and combination vaccines like DTaP to simplify schedules. Additionally, technological innovations in acellular vaccine production, improvements in cold-chain logistics, and government-supported public health initiatives create potential for new market entrants and partnerships. Manufacturers that can offer safe, effective, and easily deployable vaccines, along with reliable supply chains, are well-positioned to capture market share in both emerging and mature markets.
This report delivers a comprehensive overview of the global DPT Vaccines market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding DPT Vaccines. The DPT Vaccines market size, estimates, and forecasts are provided in terms of sales volume (M Doses) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global DPT Vaccines market comprehensively. Regional market sizes by Type, by Application, by Composition, and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist DPT Vaccines manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Sanofi Pasteur
GSK
Mitsubishi Tanabe Pharma
KM Biologics
Wuhan Institute of Biological Products
Walvax Biotechnology
Chengdu Institute of Biological Products
Minhai Biotechnology
Segment by Type
DTaP
Tdap
DTwP
Segment by Composition
Acellular Vaccines
Whole-cell Vaccines
Segment by User
Below 12 Months
Above 12 Months
by Application
Hospital
Clinic
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Composition, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for DPT Vaccines manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines DPT Vaccines sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 DPT Vaccines Market Overview
1.1 Product Definition
1.2 DPT Vaccines by Type
1.2.1 Global DPT Vaccines Market Value by Type: 2025 vs 2032
1.2.2 DTaP
1.2.3 Tdap
1.2.4 DTwP
1.3 DPT Vaccines by Composition
1.3.1 Global DPT Vaccines Market Value by Composition: 2025 vs 2032
1.3.2 Acellular Vaccines
1.3.3 Whole-cell Vaccines
1.4 DPT Vaccines by User
1.4.1 Global DPT Vaccines Market Value by User: 2025 vs 2032
1.4.2 Below 12 Months
1.4.3 Above 12 Months
1.5 DPT Vaccines by Application
1.5.1 Global DPT Vaccines Market Value by Application: 2025 vs 2032
1.5.2 Hospital
1.5.3 Clinic
1.6 Global DPT Vaccines Market Size Estimates and Forecasts
1.6.1 Global DPT Vaccines Revenue 2021–2032
1.6.2 Global DPT Vaccines Sales 2021–2032
1.6.3 Global DPT Vaccines Market Average Price (2021–2032)
1.7 Assumptions and Limitations
2 DPT Vaccines Market Competition by Manufacturers
2.1 Global DPT Vaccines Sales Market Share by Manufacturers (2021–2026)
2.2 Global DPT Vaccines Revenue Market Share by Manufacturers (2021–2026)
2.3 Global DPT Vaccines Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of DPT Vaccines, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of DPT Vaccines, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of DPT Vaccines, Product Types and Applications
2.7 Global Key Manufacturers of DPT Vaccines, Date of Entry into the Industry
2.8 Global DPT Vaccines Market Competitive Situation and Trends
2.8.1 Global DPT Vaccines Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global DPT Vaccines Players Market Share by Revenue
2.8.3 Global DPT Vaccines Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global DPT Vaccines Market Scenario by Region
3.1 Global DPT Vaccines Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global DPT Vaccines Sales by Region: 2021–2032
3.2.1 Global DPT Vaccines Sales by Region: 2021–2026
3.2.2 Global DPT Vaccines Sales by Region: 2027–2032
3.3 Global DPT Vaccines Revenue by Region: 2021–2032
3.3.1 Global DPT Vaccines Revenue by Region: 2021–2026
3.3.2 Global DPT Vaccines Revenue by Region: 2027–2032
3.4 North America DPT Vaccines Market Facts & Figures by Country
3.4.1 North America DPT Vaccines Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America DPT Vaccines Sales by Country (2021–2032)
3.4.3 North America DPT Vaccines Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe DPT Vaccines Market Facts & Figures by Country
3.5.1 Europe DPT Vaccines Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe DPT Vaccines Sales by Country (2021–2032)
3.5.3 Europe DPT Vaccines Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific DPT Vaccines Market Facts & Figures by Region
3.6.1 Asia Pacific DPT Vaccines Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific DPT Vaccines Sales by Region (2021–2032)
3.6.3 Asia Pacific DPT Vaccines Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America DPT Vaccines Market Facts & Figures by Country
3.7.1 Latin America DPT Vaccines Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America DPT Vaccines Sales by Country (2021–2032)
3.7.3 Latin America DPT Vaccines Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa DPT Vaccines Market Facts & Figures by Country
3.8.1 Middle East and Africa DPT Vaccines Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa DPT Vaccines Sales by Country (2021–2032)
3.8.3 Middle East and Africa DPT Vaccines Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global DPT Vaccines Sales by Type (2021–2032)
4.1.1 Global DPT Vaccines Sales by Type (2021–2026)
4.1.2 Global DPT Vaccines Sales by Type (2027–2032)
4.1.3 Global DPT Vaccines Sales Market Share by Type (2021–2032)
4.2 Global DPT Vaccines Revenue by Type (2021–2032)
4.2.1 Global DPT Vaccines Revenue by Type (2021–2026)
4.2.2 Global DPT Vaccines Revenue by Type (2027–2032)
4.2.3 Global DPT Vaccines Revenue Market Share by Type (2021–2032)
4.3 Global DPT Vaccines Price by Type (2021–2032)
5 Segment by Application
5.1 Global DPT Vaccines Sales by Application (2021–2032)
5.1.1 Global DPT Vaccines Sales by Application (2021–2026)
5.1.2 Global DPT Vaccines Sales by Application (2027–2032)
5.1.3 Global DPT Vaccines Sales Market Share by Application (2021–2032)
5.2 Global DPT Vaccines Revenue by Application (2021–2032)
5.2.1 Global DPT Vaccines Revenue by Application (2021–2026)
5.2.2 Global DPT Vaccines Revenue by Application (2027–2032)
5.2.3 Global DPT Vaccines Revenue Market Share by Application (2021–2032)
5.3 Global DPT Vaccines Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Sanofi Pasteur
6.1.1 Sanofi Pasteur Company Information
6.1.2 Sanofi Pasteur Description and Business Overview
6.1.3 Sanofi Pasteur DPT Vaccines Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Sanofi Pasteur DPT Vaccines Product Portfolio
6.1.5 Sanofi Pasteur Recent Developments/Updates
6.2 GSK
6.2.1 GSK Company Information
6.2.2 GSK Description and Business Overview
6.2.3 GSK DPT Vaccines Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 GSK DPT Vaccines Product Portfolio
6.2.5 GSK Recent Developments/Updates
6.3 Mitsubishi Tanabe Pharma
6.3.1 Mitsubishi Tanabe Pharma Company Information
6.3.2 Mitsubishi Tanabe Pharma Description and Business Overview
6.3.3 Mitsubishi Tanabe Pharma DPT Vaccines Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Mitsubishi Tanabe Pharma DPT Vaccines Product Portfolio
6.3.5 Mitsubishi Tanabe Pharma Recent Developments/Updates
6.4 KM Biologics
6.4.1 KM Biologics Company Information
6.4.2 KM Biologics Description and Business Overview
6.4.3 KM Biologics DPT Vaccines Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 KM Biologics DPT Vaccines Product Portfolio
6.4.5 KM Biologics Recent Developments/Updates
6.5 Wuhan Institute of Biological Products
6.5.1 Wuhan Institute of Biological Products Company Information
6.5.2 Wuhan Institute of Biological Products Description and Business Overview
6.5.3 Wuhan Institute of Biological Products DPT Vaccines Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Wuhan Institute of Biological Products DPT Vaccines Product Portfolio
6.5.5 Wuhan Institute of Biological Products Recent Developments/Updates
6.6 Walvax Biotechnology
6.6.1 Walvax Biotechnology Company Information
6.6.2 Walvax Biotechnology Description and Business Overview
6.6.3 Walvax Biotechnology DPT Vaccines Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Walvax Biotechnology DPT Vaccines Product Portfolio
6.6.5 Walvax Biotechnology Recent Developments/Updates
6.7 Chengdu Institute of Biological Products
6.7.1 Chengdu Institute of Biological Products Company Information
6.7.2 Chengdu Institute of Biological Products Description and Business Overview
6.7.3 Chengdu Institute of Biological Products DPT Vaccines Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Chengdu Institute of Biological Products DPT Vaccines Product Portfolio
6.7.5 Chengdu Institute of Biological Products Recent Developments/Updates
6.8 Minhai Biotechnology
6.8.1 Minhai Biotechnology Company Information
6.8.2 Minhai Biotechnology Description and Business Overview
6.8.3 Minhai Biotechnology DPT Vaccines Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Minhai Biotechnology DPT Vaccines Product Portfolio
6.8.5 Minhai Biotechnology Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 DPT Vaccines Industry Chain Analysis
7.2 DPT Vaccines Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 DPT Vaccines Production Mode & Process Analysis
7.4 DPT Vaccines Sales and Marketing
7.4.1 DPT Vaccines Sales Channels
7.4.2 DPT Vaccines Distributors
7.5 DPT Vaccines Customer Analysis
8 DPT Vaccines Market Dynamics
8.1 DPT Vaccines Industry Trends
8.2 DPT Vaccines Market Drivers
8.3 DPT Vaccines Market Challenges
8.4 DPT Vaccines Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global DPT Vaccines Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global DPT Vaccines Market Value by Composition (US$ Million), 2025 vs 2032
Table 3. Global DPT Vaccines Market Value by User (US$ Million), 2025 vs 2032
Table 4. Global DPT Vaccines Market Value by Application (US$ Million), 2025 vs 2032
Table 5. Global DPT Vaccines Market Competitive Situation by Manufacturers in 2025
Table 6. Global DPT Vaccines Sales (M Doses) of Key Manufacturers (2021–2026)
Table 7. Global DPT Vaccines Sales Market Share by Manufacturers (2021–2026)
Table 8. Global DPT Vaccines Revenue (US$ Million) by Manufacturers (2021–2026)
Table 9. Global DPT Vaccines Revenue Share by Manufacturers (2021–2026)
Table 10. Global Market DPT Vaccines Average Price (US$/Dose) of Key Manufacturers (2021–2026)
Table 11. Global Key Players of DPT Vaccines, Industry Ranking, 2023 vs 2024 vs 2025
Table 12. Global Key Manufacturers of DPT Vaccines, Manufacturing Sites and Headquarters
Table 13. Global Key Manufacturers of DPT Vaccines, Product Types and Applications
Table 14. Global Key Manufacturers of DPT Vaccines, Date of Entry into the Industry
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global DPT Vaccines Companies by Tier (Tier 1, Tier 2, Tier 3), based on DPT Vaccines Revenue, 2025
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 18. Global DPT Vaccines Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 19. Global DPT Vaccines Sales by Region (M Doses), 2021–2026
Table 20. Global DPT Vaccines Sales Market Share by Region (2021–2026)
Table 21. Global DPT Vaccines Sales by Region (M Doses), 2027–2032
Table 22. Global DPT Vaccines Sales Market Share by Region (2027–2032)
Table 23. Global DPT Vaccines Revenue by Region (US$ Million), 2021–2026
Table 24. Global DPT Vaccines Revenue Market Share by Region (2021–2026)
Table 25. Global DPT Vaccines Revenue by Region (US$ Million), 2027–2032
Table 26. Global DPT Vaccines Revenue Market Share by Region (2027–2032)
Table 27. North America DPT Vaccines Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 28. North America DPT Vaccines Sales by Country (M Doses), 2021–2026
Table 29. North America DPT Vaccines Sales by Country (M Doses), 2027–2032
Table 30. North America DPT Vaccines Revenue by Country (US$ Million), 2021–2026
Table 31. North America DPT Vaccines Revenue by Country (US$ Million), 2027–2032
Table 32. Europe DPT Vaccines Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 33. Europe DPT Vaccines Sales by Country (M Doses), 2021–2026
Table 34. Europe DPT Vaccines Sales by Country (M Doses), 2027–2032
Table 35. Europe DPT Vaccines Revenue by Country (US$ Million), 2021–2026
Table 36. Europe DPT Vaccines Revenue by Country (US$ Million), 2027–2032
Table 37. Asia Pacific DPT Vaccines Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 38. Asia Pacific DPT Vaccines Sales by Region (M Doses), 2021–2026
Table 39. Asia Pacific DPT Vaccines Sales by Region (M Doses), 2027–2032
Table 40. Asia Pacific DPT Vaccines Revenue by Region (US$ Million), 2021–2026
Table 41. Asia Pacific DPT Vaccines Revenue by Region (US$ Million), 2027–2032
Table 42. Latin America DPT Vaccines Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 43. Latin America DPT Vaccines Sales by Country (M Doses), 2021–2026
Table 44. Latin America DPT Vaccines Sales by Country (M Doses), 2027–2032
Table 45. Latin America DPT Vaccines Revenue by Country (US$ Million), 2021–2026
Table 46. Latin America DPT Vaccines Revenue by Country (US$ Million), 2027–2032
Table 47. Middle East and Africa DPT Vaccines Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 48. Middle East and Africa DPT Vaccines Sales by Country (M Doses), 2021–2026
Table 49. Middle East and Africa DPT Vaccines Sales by Country (M Doses), 2027–2032
Table 50. Middle East and Africa DPT Vaccines Revenue by Country (US$ Million), 2021–2026
Table 51. Middle East and Africa DPT Vaccines Revenue by Country (US$ Million), 2027–2032
Table 52. Global DPT Vaccines Sales (M Doses) by Type (2021–2026)
Table 53. Global DPT Vaccines Sales (M Doses) by Type (2027–2032)
Table 54. Global DPT Vaccines Sales Market Share by Type (2021–2026)
Table 55. Global DPT Vaccines Sales Market Share by Type (2027–2032)
Table 56. Global DPT Vaccines Revenue (US$ Million) by Type (2021–2026)
Table 57. Global DPT Vaccines Revenue (US$ Million) by Type (2027–2032)
Table 58. Global DPT Vaccines Revenue Market Share by Type (2021–2026)
Table 59. Global DPT Vaccines Revenue Market Share by Type (2027–2032)
Table 60. Global DPT Vaccines Price (US$/Dose) by Type (2021–2026)
Table 61. Global DPT Vaccines Price (US$/Dose) by Type (2027–2032)
Table 62. Global DPT Vaccines Sales (M Doses) by Application (2021–2026)
Table 63. Global DPT Vaccines Sales (M Doses) by Application (2027–2032)
Table 64. Global DPT Vaccines Sales Market Share by Application (2021–2026)
Table 65. Global DPT Vaccines Sales Market Share by Application (2027–2032)
Table 66. Global DPT Vaccines Revenue (US$ Million) by Application (2021–2026)
Table 67. Global DPT Vaccines Revenue (US$ Million) by Application (2027–2032)
Table 68. Global DPT Vaccines Revenue Market Share by Application (2021–2026)
Table 69. Global DPT Vaccines Revenue Market Share by Application (2027–2032)
Table 70. Global DPT Vaccines Price (US$/Dose) by Application (2021–2026)
Table 71. Global DPT Vaccines Price (US$/Dose) by Application (2027–2032)
Table 72. Sanofi Pasteur Company Information
Table 73. Sanofi Pasteur Description and Business Overview
Table 74. Sanofi Pasteur DPT Vaccines Sales (M Doses), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 75. Sanofi Pasteur DPT Vaccines Product
Table 76. Sanofi Pasteur Recent Developments/Updates
Table 77. GSK Company Information
Table 78. GSK Description and Business Overview
Table 79. GSK DPT Vaccines Sales (M Doses), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 80. GSK DPT Vaccines Product
Table 81. GSK Recent Developments/Updates
Table 82. Mitsubishi Tanabe Pharma Company Information
Table 83. Mitsubishi Tanabe Pharma Description and Business Overview
Table 84. Mitsubishi Tanabe Pharma DPT Vaccines Sales (M Doses), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 85. Mitsubishi Tanabe Pharma DPT Vaccines Product
Table 86. Mitsubishi Tanabe Pharma Recent Developments/Updates
Table 87. KM Biologics Company Information
Table 88. KM Biologics Description and Business Overview
Table 89. KM Biologics DPT Vaccines Sales (M Doses), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 90. KM Biologics DPT Vaccines Product
Table 91. KM Biologics Recent Developments/Updates
Table 92. Wuhan Institute of Biological Products Company Information
Table 93. Wuhan Institute of Biological Products Description and Business Overview
Table 94. Wuhan Institute of Biological Products DPT Vaccines Sales (M Doses), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 95. Wuhan Institute of Biological Products DPT Vaccines Product
Table 96. Wuhan Institute of Biological Products Recent Developments/Updates
Table 97. Walvax Biotechnology Company Information
Table 98. Walvax Biotechnology Description and Business Overview
Table 99. Walvax Biotechnology DPT Vaccines Sales (M Doses), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 100. Walvax Biotechnology DPT Vaccines Product
Table 101. Walvax Biotechnology Recent Developments/Updates
Table 102. Chengdu Institute of Biological Products Company Information
Table 103. Chengdu Institute of Biological Products Description and Business Overview
Table 104. Chengdu Institute of Biological Products DPT Vaccines Sales (M Doses), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 105. Chengdu Institute of Biological Products DPT Vaccines Product
Table 106. Chengdu Institute of Biological Products Recent Developments/Updates
Table 107. Minhai Biotechnology Company Information
Table 108. Minhai Biotechnology Description and Business Overview
Table 109. Minhai Biotechnology DPT Vaccines Sales (M Doses), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 110. Minhai Biotechnology DPT Vaccines Product
Table 111. Minhai Biotechnology Recent Developments/Updates
Table 112. Key Raw Materials Lists
Table 113. Raw Materials Key Suppliers Lists
Table 114. DPT Vaccines Distributors List
Table 115. DPT Vaccines Customers List
Table 116. DPT Vaccines Market Trends
Table 117. DPT Vaccines Market Drivers
Table 118. DPT Vaccines Market Challenges
Table 119. DPT Vaccines Market Restraints
Table 120. Research Programs/Design for This Report
Table 121. Key Data Information from Secondary Sources
Table 122. Key Data Information from Primary Sources
Table 123. Authors List of This Report
List of Figures
Figure 1. Product Picture of DPT Vaccines
Figure 2. Global DPT Vaccines Market Value by Type (US$ Million), 2021–2032
Figure 3. Global DPT Vaccines Market Share by Type: 2025 & 2032
Figure 4. DTaP Product Picture
Figure 5. Tdap Product Picture
Figure 6. DTwP Product Picture
Figure 7. Global DPT Vaccines Market Value by Composition (US$ Million), 2021–2032
Figure 8. Global DPT Vaccines Market Share by Composition: 2025 vs 2032
Figure 9. Acellular Vaccines Product Picture
Figure 10. Whole-cell Vaccines Product Picture
Figure 11. Global DPT Vaccines Market Value by User (US$ Million), 2021–2032
Figure 12. Global DPT Vaccines Market Share by User: 2025 vs 2032
Figure 13. Below 12 Months Product Picture
Figure 14. Above 12 Months Product Picture
Figure 15. Global DPT Vaccines Market Value by Application (US$ Million), 2021–2032
Figure 16. Global DPT Vaccines Market Share by Application: 2025 & 2032
Figure 17. Hospital
Figure 18. Clinic
Figure 19. Global DPT Vaccines Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 20. Global DPT Vaccines Market Size (US$ Million), 2021–2032
Figure 21. Global DPT Vaccines Sales (M Doses), 2021–2032
Figure 22. Global DPT Vaccines Average Price (US$/Dose), 2021–2032
Figure 23. DPT Vaccines Report Years Considered
Figure 24. DPT Vaccines Sales Share by Manufacturers in 2025
Figure 25. Global DPT Vaccines Revenue Share by Manufacturers in 2025
Figure 26. Top 5 and Top 10 Global DPT Vaccines Players: Market Share by Revenue in DPT Vaccines in 2025
Figure 27. DPT Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 28. Global DPT Vaccines Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 29. North America DPT Vaccines Sales Market Share by Country (2021–2032)
Figure 30. North America DPT Vaccines Revenue Market Share by Country (2021–2032)
Figure 31. United States DPT Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Canada DPT Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Europe DPT Vaccines Sales Market Share by Country (2021–2032)
Figure 34. Europe DPT Vaccines Revenue Market Share by Country (2021–2032)
Figure 35. Germany DPT Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. France DPT Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. U.K. DPT Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. Italy DPT Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. Russia DPT Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Asia Pacific DPT Vaccines Sales Market Share by Region (2021–2032)
Figure 41. Asia Pacific DPT Vaccines Revenue Market Share by Region (2021–2032)
Figure 42. China DPT Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Japan DPT Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. South Korea DPT Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. India DPT Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Australia DPT Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. China Taiwan DPT Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Indonesia DPT Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Thailand DPT Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Malaysia DPT Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Latin America DPT Vaccines Sales Market Share by Country (2021–2032)
Figure 52. Latin America DPT Vaccines Revenue Market Share by Country (2021–2032)
Figure 53. Mexico DPT Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Brazil DPT Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. Argentina DPT Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 56. Middle East and Africa DPT Vaccines Sales Market Share by Country (2021–2032)
Figure 57. Middle East and Africa DPT Vaccines Revenue Market Share by Country (2021–2032)
Figure 58. Turkey DPT Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 59. Saudi Arabia DPT Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 60. UAE DPT Vaccines Revenue Growth Rate (US$ Million), 2021–2032
Figure 61. Global Sales Market Share of DPT Vaccines by Type (2021–2032)
Figure 62. Global Revenue Market Share of DPT Vaccines by Type (2021–2032)
Figure 63. Global DPT Vaccines Price (US$/Dose) by Type (2021–2032)
Figure 64. Global Sales Market Share of DPT Vaccines by Application (2021–2032)
Figure 65. Global Revenue Market Share of DPT Vaccines by Application (2021–2032)
Figure 66. Global DPT Vaccines Price (US$/Dose) by Application (2021–2032)
Figure 67. DPT Vaccines Value Chain
Figure 68. Channels of Distribution (Direct Vs Distribution)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
